Sign In
Buy SONN
$1.26
+0 (+0%)
At Close: Feb 27, 2026
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
04:30pm, Tuesday, 02'nd Dec 2025
Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker “PURR” Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on
PRINCETON, N. J. , Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. , (NASDAQ: SONN) ("Sonnet" or the "Company") today announced that its stockholders approved, among other thin
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
09:00am, Tuesday, 18'th Nov 2025
PRINCETON, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has adjourned its special meeting o
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
10:03am, Wednesday, 15'th Oct 2025
HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patie
Sonnet to Present at the MedInvest Biotech & Pharma Conference
09:00am, Friday, 19'th Sep 2025
PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targete
Sonnet Releases Virtual Investor "What This Means" Segment
09:15am, Monday, 11'th Aug 2025
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
08:40am, Monday, 04'th Aug 2025
Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (Tecentriq ® ) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)
06:54pm, Monday, 14'th Jul 2025
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?
11:30am, Monday, 14'th Jul 2025
Sonnet BioTherapeutics Inc. SONN stock surged Monday amid high trading volume following news of a transformative business combination with Rorschach I, backed by Atlas Merchant Capital and Paradigm.
This stock rockets 260% after $900 million mega crypto deal
08:18am, Monday, 14'th Jul 2025
Shares of Sonnet BioTherapeutics (NASDAQ: SONN) soared in pre-market trading on Monday after the company announced a $888 million business combination to pivot into the cryptocurrency sector.
SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders
08:02am, Monday, 14'th Jul 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN) and Rorschach I LLC is fair to Sonnet share
Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury Combined company expected to become largest U.S.-based publicly listed company to hold HYPE
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
09:00am, Thursday, 01'st May 2025
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting
Sonnet Releases Virtual Investor "What This Means" Segment
09:10am, Wednesday, 16'th Apr 2025
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® )
